Core Viewpoint - Changjiang Life Science Technology (00775) saw a stock increase of over 7%, currently trading at 1.07 HKD with a transaction volume of 11.2495 million HKD, following the announcement of a significant transaction involving TransCode Therapeutics, Inc. [1] Group 1: Transaction Details - Changjiang Life Science Technology announced the sale of 100% equity in ABCJ, LLC to TransCode Therapeutics, Inc. for a total consideration of 125 million USD [1] - The payment will be made through the issuance of 83,285 common shares and 1,153 Series A preferred shares [1] - The company will also purchase 223.73 shares of Series B preferred stock from RNAZ for a total of 25 million USD [1] Group 2: Ownership and Shareholding Changes - Following the issuance of common shares, the company will hold 9.1% of common stock in RNAZ, which will increase to 90.7% after the full conversion of preferred shares [1] Group 3: Product Pipeline and Business Merger - The merger will combine the operations of Polynoma, which is wholly owned by ABCJ, LLC, with RNAZ, creating a diverse therapeutic product portfolio [1] - Polynoma's flagship therapeutic candidate, seviprotimut-L, is a cancer vaccine targeting melanoma, while RNAZ's product line includes its flagship candidate TTX-MC138 and several other candidates in preclinical stages [1]
长江生命科技涨超7% Polynoma与RNAZ业务合并